<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05618561</url>
  </required_header>
  <id_info>
    <org_study_id>CT013</org_study_id>
    <nct_id>NCT05618561</nct_id>
  </id_info>
  <brief_title>EuGeni Rapid Antigen Test for the Qualitative Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Causing COVID19 Disease in Compliance With the World Health Organization (WHO)</brief_title>
  <acronym>WHO</acronym>
  <official_title>EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test Clinical Performance Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AnteoTech Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AnteoTech Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rapid antigen detection (RAD) tests are used to perform rapid diagnosis of SARS-CoV-2&#xD;
      infection based on a qualitative approach. RAD tests detect the viral antigen by the&#xD;
      immobilized coated SARS-CoV-2 antibody placed on the device. The results of these tests are&#xD;
      available in a short time, reducing the workload in diagnostic hospitals and laboratories and&#xD;
      improving the turn-around time.&#xD;
&#xD;
      EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test is an in vitro Diagnostic (IVD) medical&#xD;
      device intended to be used for the qualitative detection of SARS-CoV-2 nucleocapsid antigen.&#xD;
      The result from this IVD test identifies the presence or absence of the SARS-CoV-2 antigen as&#xD;
      an aid for the diagnosis of COVID-19 infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The EuGeni SARS-CoV-2 Antigen (Ag) Rapid Detection Test (RDT) is a test strip based on&#xD;
      lateral flow technology which utilizes nanoparticles, doped with europium, as the&#xD;
      fluorescence reporter system. The test strip is housed in a cassette which is read by the&#xD;
      EuGeni AX-2X-S Reader, a portable instrument that reads EuGeni fluorescent lateral flow&#xD;
      tests.&#xD;
&#xD;
      The test line contains an immobilized monoclonal mouse antibody to capture SARS-CoV-2 antigen&#xD;
      and the control line contains an immobilized control anti-mouse antibody.&#xD;
&#xD;
      The test sample is added to the sample well of the test cassette and then reconstitutes the&#xD;
      dried europium nanoparticle antibody conjugate from the conjugate pad. The sample flows along&#xD;
      the test strip by capillary action.&#xD;
&#xD;
      If the sample contains SARS-CoV-2 antigen, it binds to the antibody-labelled europium&#xD;
      nanoparticle. When the sample flows past the test line, the europium bound antigen is&#xD;
      captured by the second anti-SARS-CoV-2 antibody immobilized on the test line. A fluorescent&#xD;
      signal detected by the EuGeni AX-2X-S Reader at this test line indicates that the specimen is&#xD;
      SARS-CoV-2 antigen Positive.&#xD;
&#xD;
      If the sample does not contain SARS-CoV-2 antigen, the europium-labelled anti-antigen&#xD;
      antibody will not bind to the test line. This indicates that the specimen is SARS-CoV-2&#xD;
      antigen Negative.&#xD;
&#xD;
      The sample continues to flow along the strip and when it passes over the control line,&#xD;
      antibody-labelled europium nanoparticles are captured by the immobilized anti-mouse antibody.&#xD;
      The control line must be detected by the EuGeni AX-2X-S Reader for the test to be valid. If&#xD;
      the control line is not detected, the test is considered invalid and must be repeated using&#xD;
      another test cassette.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    High number of false negatives&#xD;
  </why_stopped>
  <start_date type="Actual">July 26, 2022</start_date>
  <completion_date type="Actual">November 2, 2022</completion_date>
  <primary_completion_date type="Actual">August 25, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic sensitivity and specificity in terms of true positive results and true negative results between the kit under investigation and the gold-standard PCR</measure>
    <time_frame>Through study completion, an average of 4 months</time_frame>
    <description>Number of true positives and true negatives in terms of sensitivity and specificity (accuracy) by contrasting the result obtained with the investigational kit and the gold-standard PCR result.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The sensitivity and the specificity values between the two collection methods, nasal and nasopharyngeal.</measure>
    <time_frame>Through study completion, an average of 4 months</time_frame>
    <description>To compare the sensitivity and specificity value translated as true positives and true negatives between the investigational kit and PCR between the two sample collection methods, nasal and nasopharyngeal.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">599</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Nasopharyngeal specimen collection arm</arm_group_label>
    <description>Specimens collected in nasopharyngeal form from positive subjects with symptoms and negative subjects hospitalized and negative subjects with respiratory symptoms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined nasal mid-turbinate and throat specimen collection arm</arm_group_label>
    <description>Specimens collected in combined nasal mid-turbinate form from positive subjects with symptoms and negative subjects hospitalized and negative subjects with respiratory symptoms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test</intervention_name>
    <description>Subjects have two swabs taken for analysis, one (combined or nasopharyngeal) with the kit under investigation and the other (by standard of care) for analysis with PCRl.</description>
    <arm_group_label>Combined nasal mid-turbinate and throat specimen collection arm</arm_group_label>
    <arm_group_label>Nasopharyngeal specimen collection arm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The entire population over 12 years of age that met the inclusion criteria and none of the&#xD;
        exclusion criteria. Positive subjects must present COVID19 symptoms. In the case of&#xD;
        negative subjects, one part must be hospitalized (for any reason) and the other part must&#xD;
        have respiratory symptoms.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Specimens from subjects over 12 years old agreeing to participate in the study and&#xD;
             with a legal representative able to provide informed consent, OR;&#xD;
&#xD;
          2. Specimens from subjects over 18 years old able to provide informed consent.&#xD;
&#xD;
          3. Specimens collected with nasopharyngeal swabs, OR;&#xD;
&#xD;
          4. Combined nasal mid-turbinate and throat specimen collection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Specimens and testing methods that are not deemed to be in line with gold-standard&#xD;
             RT-PCR standards.&#xD;
&#xD;
          2. Specimens stored for over 2 hours at 2-8 ºC temperature between collection and testing&#xD;
             with EuGeni SARS-CoV-2 Ag RDT.&#xD;
&#xD;
          3. Specimens stored for over 5 days at -20ºC between collection and testing with RT-PCR.&#xD;
&#xD;
          4. Specimens stored for over 24h at 4ºC between collection and testing with RT-PCR.&#xD;
&#xD;
          5. Contamination and/or deterioration of the specimen which, in the opinion of the&#xD;
             investigator, may affect its handling and/or analysis.&#xD;
&#xD;
          6. The subject is deemed unsuitable to participate in the study by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Antonia Sánchez Calavera</last_name>
    <role>Principal Investigator</role>
    <affiliation>C.S. Fuentes Norte</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Virion</name>
      <address>
        <city>Split</city>
        <zip>21213</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laiko General Hospital</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Salud Fuentes Norte</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <zip>50002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Salud Torre Ramona</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <zip>50013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de A Coruña (CHUAC)</name>
      <address>
        <city>A Coruña</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Greece</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>November 10, 2022</study_first_submitted>
  <study_first_submitted_qc>November 15, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>January 3, 2023</last_update_submitted>
  <last_update_submitted_qc>January 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>covid19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 19, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT05618561/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

